Temporal trends with the Evolut family of self-expanding transcatheter heart valves: A single-center experience.
TAVR
aortic stenosis
self‐expanding valve
Journal
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions
ISSN: 1522-726X
Titre abrégé: Catheter Cardiovasc Interv
Pays: United States
ID NLM: 100884139
Informations de publication
Date de publication:
20 May 2024
20 May 2024
Historique:
revised:
29
03
2024
received:
01
09
2023
accepted:
08
05
2024
medline:
21
5
2024
pubmed:
21
5
2024
entrez:
21
5
2024
Statut:
aheadofprint
Résumé
The Evolut self-expanding valve (SEV) systems (Medtronic), were designed to accommodate varying valve sizes and reduce paravalvular leak (PVL) while maintaining a low delivery profile. These systems have evolved between product generations, alongside valve deployment techniques changing over time. This study aimed to examine whether these changes impacted clinical outcomes. EPROMPT is a prospective, investigator-initiated, postmarketing registry of consecutive patients undergoing transfemoral transcatheter aortic valve replacement (TAVR) using the Evolut PRO/PRO+ SEV system. A total of 300 patients were divided into three consecutive cohorts of 100 patients according to implantation date (January to October 2018, November 2018 to July 2020, and August 2020 to November 2021). Procedural and clinical outcomes over these time periods were compared. Valve Academic Research Consortium (VARC)-2 device implantation success improved over time (70.0% vs. 78.0% vs. 88.8%, p = 0.01), with a similar trend for VARC-3 device success (94.7% vs. 81.7% vs. 96.8%, p < 0.001). PVL (all degrees) frequency was likewise reduced over time (31.0% vs. 17.0% vs. 19.2%, p = 0.04). Furthermore, a trend was noticed toward shorter procedure times and shorter length of stay. However, postprocedural pacemaker implantation rates did not significantly differ (15.2% vs. 21.1% vs. 14.0%, p = 0.43). During a 3-year period, we demonstrated better TAVR outcomes with newer SEV iterations, alongside changes in implantation techniques, which might result in better procedural and clinical outcomes. However, we did not see a significant change in peri-procedural pacemaker rates for SEV.
Sections du résumé
BACKGROUND
BACKGROUND
The Evolut self-expanding valve (SEV) systems (Medtronic), were designed to accommodate varying valve sizes and reduce paravalvular leak (PVL) while maintaining a low delivery profile. These systems have evolved between product generations, alongside valve deployment techniques changing over time.
AIMS
OBJECTIVE
This study aimed to examine whether these changes impacted clinical outcomes.
METHODS
METHODS
EPROMPT is a prospective, investigator-initiated, postmarketing registry of consecutive patients undergoing transfemoral transcatheter aortic valve replacement (TAVR) using the Evolut PRO/PRO+ SEV system. A total of 300 patients were divided into three consecutive cohorts of 100 patients according to implantation date (January to October 2018, November 2018 to July 2020, and August 2020 to November 2021). Procedural and clinical outcomes over these time periods were compared.
RESULTS
RESULTS
Valve Academic Research Consortium (VARC)-2 device implantation success improved over time (70.0% vs. 78.0% vs. 88.8%, p = 0.01), with a similar trend for VARC-3 device success (94.7% vs. 81.7% vs. 96.8%, p < 0.001). PVL (all degrees) frequency was likewise reduced over time (31.0% vs. 17.0% vs. 19.2%, p = 0.04). Furthermore, a trend was noticed toward shorter procedure times and shorter length of stay. However, postprocedural pacemaker implantation rates did not significantly differ (15.2% vs. 21.1% vs. 14.0%, p = 0.43).
CONCLUSION
CONCLUSIONS
During a 3-year period, we demonstrated better TAVR outcomes with newer SEV iterations, alongside changes in implantation techniques, which might result in better procedural and clinical outcomes. However, we did not see a significant change in peri-procedural pacemaker rates for SEV.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Medtronic
Informations de copyright
© 2024 Wiley Periodicals LLC.
Références
Waksman R, Corso PJ, Torguson R, et al. TAVR in low‐risk patients. JACC Cardiovasc Interv. 2019;12:901‐907.
Wyler von Ballmoos MC, Reardon MJ, Williams MR, et al. Three‐year outcomes with a contemporary self‐expanding transcatheter valve from the Evolut PRO US clinical study. Cardiovasc Revasc Med. 2021;26:12‐16.
Forrestal BJ, Case BC, Yerasi C, et al. Risk of coronary obstruction and feasibility of coronary access after repeat transcatheter aortic valve replacement with the self‐expanding evolut valve: a computed tomography simulation study. Circ Cardiovasc Interv. 2020;13:e009496.
Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. Circulation. 2021;143:e72‐e227.
Kappetein AP, Head SJ, Genereux P, et al. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium‐2 consensus document (VARC‐2). Eur J Cardiothorac Surg. 2012;42:S45‐S60.
VARC‐3 Writing Committee, Généreux P, Piazza N, et al. Valve Academic Research Consortium 3: updated endpoint definitions for aortic valve. J Am Coll Cardiol. 2021;77:2717‐2746.
Popma JJ, Adams DH, Reardon MJ, et al. Transcatheter aortic valve replacement using a self‐expanding bioprosthesis in patients with severe aortic stenosis at extreme risk for surgery. J Am Coll Cardiol. 2014;63:1972‐1981.
Popma JJ, Reardon MJ, Khabbaz K, et al. Early clinical outcomes after transcatheter aortic valve replacement using a novel self‐expanding bioprosthesis in patients with severe aortic stenosis who are suboptimal for surgery. JACC Cardiovasc Interv. 2017;10:268‐275.
Forrest JK, Deeb GM, Yakubov SJ, et al. 2‐year outcomes after transcatheter versus surgical aortic valve replacement in low‐risk patients. J Am Coll Cardiol. 2022;79:882‐896.
Salemi A, Sedrakyan A, Mao J, et al. Individual operator experience and outcomes in transcatheter aortic valve replacement. JACC: Cardiovasc Interv. 2019;12:90‐97.
Lerakis S, Hayek SS, Douglas PS. Paravalvular aortic leak after transcatheter aortic valve replacement: current knowledge. Circulation. 2013;127:397‐407.
Athappan G, Patvardhan E, Tuzcu EM, et al. Incidence, predictors, and outcomes of aortic regurgitation after transcatheter aortic valve replacement. J Am Coll Cardiol. 2013;61:1585‐1595.
Kalogeras K, Ruparelia N, Kabir T, et al. Comparison of the self‐expanding Evolut‐PRO transcatheter aortic valve to its predecessor Evolut‐R in the real world multicenter ATLAS registry. Int J Cardiol. 2020;310:120‐125.
Attizzani GF, Dallan LAP, Markowitz A, et al. Impact of repositioning on outcomes following transcatheter aortic valve replacement with a self‐expandable valve. JACC: Cardiovasc Interv. 2020;13:1816‐1824.
Grubb KJ, Gada H, Mittal S, et al. Clinical impact of standardized TAVR technique and care pathway. JACC: Cardiovasc Interv. 2023;16:558‐570.
Medranda GA, Rogers T, Case BC, et al. The impact of cusp overlap on permanent pacemaker requirement following self‐expanding transcatheter aortic valve replacement. Cardiovasc Revasc Med. Published online July 29, 2023. doi:10.1016/j.carrev.2023.07.018
Ullah W, Zahid S, Zaidi SR, et al. Predictors of permanent pacemaker implantation in patients undergoing transcatheter aortic valve replacement—a systematic review and meta‐analysis. J Am Heart Assoc. 2021;10:e020906.
Lilly SM, Deshmukh AJ, Epstein AE, et al. 2020 ACC expert consensus decision pathway on management of conduction disturbances in patients undergoing transcatheter aortic valve replacement: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol, 2020(76):2391‐2411.
Glikson M, Nielsen JC, Kronborg MB, et al. 2021 ESC guidelines on cardiac pacing and cardiac resynchronization therapy. Eur Heart J, 2021(42):3427‐3520.
Danenberg HD. Pay attention on the road: TAVR and vascular complications. Cardiovasc Revasc Med. 2020;21:1074‐1075.
Laakso T, Moriyama N, Raivio P, et al. Impact of major vascular complication access site status on mortality after transfemoral transcatheter aortic valve replacement—results from the FinnValve registry. Circ Rep. 2020;2:182‐191.
van Wiechen MP, Kroon H, Hokken TW, et al. Vascular complications with a plug‐based vascular closure device after transcatheter aortic valve replacement: predictors and bail‐outs. Catheter Cardiovasc Interv. 2021;98:E737‐e745.
Megaly M, Sedhom R, Abdelmaseeh P, et al. Complications of the MANTA closure device: insights from MAUDE database. Cardiovasc Revasc Med. 2022;34:75‐79.
Hellhammer K, Piayda K, Afzal S, et al. The latest evolution of the Medtronic CoreValve system in the era of transcatheter aortic valve replacement. JACC: Cardiovasc Interv. 2018;11:2314‐2322.
Forrest JK, Kaple RK, Tang GHL, et al. Three generations of self‐expanding transcatheter aortic valves. JACC: Cardiovasc Interv. 2020;13:170‐179.
Deharo P, Bisson A, Herbert J, et al. Impact of Sapien 3 balloon‐expandable versus evolut R self‐expandable transcatheter aortic valve implantation in patients with aortic stenosis. Circulation. 2020;141:260‐268.
Rheude T, Pellegrini C, Allali A, et al. Multicenter comparison of latest‐generation balloon‐expandable versus self‐expanding transcatheter heart valves: ultra versus evolut. Int J Cardiol. 2022;357:115‐120.
Scotti A, Baggio S, Pagnesi M, et al. Temporal trends and contemporary outcomes after transcatheter aortic valve replacement with evolut PRO/PRO+ self‐expanding valves: insights from the NEOPRO/NEOPRO‐2 registries. Circulation: Cardiovasc Interv. 2023;16:e012538.
Panagides V, Mesnier J, Nuche J, et al. From the Evolut Pro to the Evolut FX self‐expanding transcatheter aortic valve replacement systems: current status and future perspectives. Expert Rev Med Devices. 2022;19:561‐569.
Khera S, Krishnamoorthy P, Sharma SK, et al. Improved commissural alignment in TAVR with the newest evolut FX self‐expanding supra‐annular valve. JACC: Cardiovasc Interv. 2023;16:498‐500.
Merdler I, Case B, Bhogal S, et al. Early experience with the Evolut FX self‐expanding valve vs. Evolut PRO+ for patients with aortic stenosis undergoing TAVR. Cardiovasc Revasc Med. Published online June 5, 2023. doi:10.1016/j.carrev.2023.06.003
Tang GHL, Amat‐Santos IJ, De Backer O, De Backer O, et al. Rationale, definitions, techniques, and outcomes of commissural alignment in TAVR. JACC: Cardiovasc Interv. 2022;15:1497‐1518.
Coylewright M, Forrest JK, McCabe JM, Nazif TM. TAVR in low‐risk patients. J Am Coll Cardiol. 2020;75:1208‐1211.
Rogers T, Shults C, Torguson R, et al. Randomized trial of aspirin versus warfarin after transcatheter aortic valve replacement in low‐risk patients. Circ: Cardiovasc Interv. 2021;14:e009983.